Mounjaro Weight Loss: What SURMOUNT and Labels Show

Mounjaro is approved for type 2 diabetes, yet it is famous for weight loss. This page sorts out that apparent contradiction: what the Mounjaro label actually covers, where the big tirzepatide weight figures come from, and how Zepbound fits into the story. It is education only, not medical advice.

Mounjaro is a diabetes medicine first

Mounjaro is the brand name for tirzepatide, a once weekly injection approved to improve blood sugar control in adults with type 2 diabetes. Its dosing schedule starts at 2.5 mg and can rise in 2.5 mg steps to a maximum of 15 mg once weekly, with the pace set by the prescriber. Weight management is not an approved use on the Mounjaro label. As with Ozempic, though, weight moved in the diabetes trials, because tirzepatide strongly reduces appetite and slows stomach emptying, and the effect was large enough to justify a dedicated weight management program for the same drug.

That program produced Zepbound, which contains the same tirzepatide, in the same kind of pen, but carries the weight management label. Almost everything impressive you have read about Mounjaro weight loss traces back to the Zepbound trial program, called SURMOUNT, rather than to the diabetes studies behind Mounjaro itself. Understanding which label and which trial a number belongs to is the key to reading tirzepatide results without being misled.

How much weight can you lose on Mounjaro

Start with what the diabetes evidence shows in words. In the trials behind the Mounjaro label, body weight fell on average at every dose studied, alongside improvements in blood sugar, and higher doses generally produced larger falls than lower doses. The label, however, does not carry a headline weight loss figure, because weight was not the outcome the approval rested on. People taking Mounjaro for diabetes commonly do lose weight, sometimes a substantial amount over a year or more of treatment, but there is no honest single percentage to quote for the diabetes population as a whole.

The quantified tirzepatide evidence comes from SURMOUNT-1, the large weight management trial run in adults without diabetes. At the 15 mg dose, the highest studied, participants lost an average of 20.9 percent of their body weight at 72 weeks, with diet and activity support. Lower doses in the same program averaged less, in a clear dose related pattern. Because SURMOUNT-1 used the Zepbound dosing and enrolled people specifically for weight management, its figures describe tirzepatide at full weight management dosing. They are the best evidence of what the drug can do, and simultaneously not a promise of what Mounjaro treatment for diabetes will deliver for any one person.

Mounjaro and Zepbound are the same drug

The two brands share one active ingredient, tirzepatide, one weekly schedule shape, and one maximum dose of 15 mg. The Zepbound label names maintenance doses of 5 mg, 10 mg or 15 mg once weekly for weight management, and Zepbound is additionally approved for moderate to severe obstructive sleep apnea in adults with obesity. The Mounjaro label is written around blood sugar goals, with dose increases guided by glucose control and tolerability. Same molecule, different approved jobs, different trial evidence, and often different insurance treatment.

Practically, this means a prescriber treating weight as the primary goal will usually reach for the Zepbound label, while a prescriber treating diabetes may prescribe Mounjaro and welcome the weight effect alongside. Some prescribers use Mounjaro off label for weight in people without diabetes, which raises the same coverage issues described for other off label GLP-1 use. The comparison page on this site, Mounjaro versus Zepbound, walks through the label differences in more detail.

Reading tirzepatide and semaglutide results side by side

People naturally want to compare the tirzepatide figure with the semaglutide one. For the record, the semaglutide weight management trial, STEP 1, reported an average loss of 14.9 percent at 68 weeks on the 2.4 mg dose, while SURMOUNT-1 reported 20.9 percent at 72 weeks on tirzepatide 15 mg. These figures come from separate trials and are not a head to head comparison. The studies enrolled different people, ran for different lengths of time, and were not designed to test the drugs against each other, so the gap between the two numbers is not a measured drug versus drug difference.

The useful takeaway is simpler. Both drugs produced large average losses in their own weight management programs, tirzepatide dosing goes to higher milligram amounts on a different scale, and individual response varies enough that the trial league table is a poor way to choose between them. Tolerability, other conditions, supply and cost usually matter more in a real prescribing decision than the difference between two averages from separate studies.

What shapes your own result

Dose is the first factor. Tirzepatide doses rise by 2.5 mg at a time, no faster than every four weeks, so reaching the higher doses takes the better part of a year even without pauses, and many people settle at a middle dose because it balances effect and side effects well for them. Time is the second factor, since the SURMOUNT average was measured at 72 weeks. The third is everything around the medicine: protein intake, portion habits, activity, sleep, and other medicines that can push weight in either direction. Diabetes itself also changes the context, because blood sugar medicines used alongside can affect weight independently.

It is also worth knowing that appetite effects and weight effects do not always move together week by week. Many people feel the appetite change within the first doses, while the scale responds gradually and unevenly, with plateaus that resolve on their own. Weighing progress monthly rather than daily gives a truer picture, and the GLP-1 weight loss calculator on this site can show what a trial average percentage would mean at your own starting weight, as arithmetic rather than prediction.

Cautions that apply to tirzepatide

Tirzepatide carries the class boxed warning about thyroid C cell tumors, and it should not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. The common effects are gastrointestinal, including nausea, vomiting, diarrhea and constipation, and they cluster around dose increases, which is why the schedule rises slowly and why prescribers sometimes hold a dose for longer. Because stomach emptying slows, oral medicines, including oral contraceptives, can be absorbed differently, a point your pharmacist can explain for your specific medicines. Any decision to start, continue or stop belongs with your own doctor, who can weigh these points against your history.

Frequently asked questions

Back to all GLPKit guides